Narrow Results

Humans make extensive use of auditory cues to interact with other humans, especially in challenging real-world acoustic environments. Multiple distinct acoustic events usually mix together in a complex auditory scene. The ability to separate and localize mixed sound in complex auditory scenes remains a demanding skill for binaural robots. In fact, binaural robots are required to disambiguate and interpret the environmental scene with only two sensors. At the same time, robots that interact with humans should be able to gain insights about the speakers in the environment, such as how many speakers are present and where they are located. For this reason, the speech signal is distinctly important among auditory stimuli commonly found in human-centered acoustic environments. In this paper, we propose a Bayesian method of selectively processing acoustic data that exploits the characteristic amplitude envelope dynamics of human speech to infer the location of speakers in the complex auditory scene. The goal was to demonstrate the effectiveness of this speech-specific temporal dynamics approach. Further, we measure how effective this method is in comparison with more traditional methods based on amplitude detection only.

We present a fully automated AI-based system for intensive monitoring of cognitive symptoms of neurotoxicity that frequently appear as a result of immunotherapy of hematologic malignancies. Early manifestations of these symptoms are evident in the patient’s speech in the form of mild aphasia and confusion and can be detected and effectively treated prior to onset of more serious and potentially life-threatening impairment. We have developed the Automated Neural Nursing Assistant (ANNA) system designed to conduct a brief cognitive assessment several times per day over the telephone for 5-14 days following infusion of the immunotherapy medication. ANNA uses a conversational agent based on a large language model to elicit spontaneous speech in a semi-structured dialogue, followed by a series of brief language-based neurocognitive tests. In this paper we share ANNA’s design and implementation, results of a pilot functional evaluation study, and discuss technical and logistic challenges facing the introduction of this type of technology in clinical practice. A large-scale clinical evaluation of ANNA will be conducted in an observational study of patients undergoing immunotherapy at the University of Minnesota Masonic Cancer Center starting in the Fall 2023.